Safety and Efficacy of Pletal (Cilostazol) for the Treatment of Juvenile Primary and Secondary Raynaud's Phenomenon
Status:
Completed
Trial end date:
2003-06-01
Target enrollment:
Participant gender:
Summary
Juvenile secondary Raynaud's (ray-knows) Phenomenon is a disorder of the blood vessels in the
fingers and sometimes can affect the toes, nose, or ears. Children with secondary Raynaud's
Phenomenon have an underlying condition such as systemic lupus, scleroderma, or mixed
connective tissue disease. When children with secondary Raynaud's are exposed to chilly or
cold conditions from weather, cold temperatures, or even holding cold items from the
refrigerator, their fingers may become cold, numb, hurt, and/or turn purple or white. The
investigational drug, Pletal(cilostazol), which has been approved for other conditions,
inhibits the ability of one type of blood cell, platelets, to form blood clots, and also
widens narrowed blood vessels. It has been used in a variety of other conditions in which
blood flow is decreased. This study will test the safety and effectiveness Pletal(cilostazol)
to lessen the severity of the symptoms and decrease the number of secondary Raynaud's
episodes in juvenile patients.